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Abstract It is attractive to use vitamin B12 as a carrier for
targeted delivery of cytotoxic agents such as platinum
complexes owing to the high demand for vitamin B12 by fast
proliferating cells. The basic {B12–CN–Pt
II} conjugates are
recognized by intracellular enzymes and converted to
coenzyme B12 in an enzymatic adenosylation assay. The
reductive adenosylation of {B12–CN–Pt
II} conjugates leads
to the release of the PtII complexes; thus, {B12–CN–Pt
II}
conjugates can be considered as prodrugs. It is important not
only to elucidate the activity of the cisplatin–B12 conjugates,
but also to understand the mode of action on a molecular
level. Chemical reduction of {B12–CN–Pt
II} conjugates with
cobaltocene yielded cob(II)alamin and induced release of the
corresponding PtII species. Kurnakov tests and coordination
of 20-deoxyguanosine or GMP to the released PtII complexes
allowed isolation and characterization of PtII complexes as
released during enzymatic adenosylation. The biological
activity of these PtII complexes was evaluated. Since the
cleaved PtII complexes show cytotoxicity, the {B12–CN–
PtII} conjugates can be used for specific targeting of cancer
cells and therapeutic drug delivery. Preliminary in vitro
cytotoxicity studies indicated lower activity (IC50 between 8
and 88 lM) than found for pure cisplatin. Since active
transport and receptor-mediated uptake limits the intracel-
lular {B12–CN–Pt
II} concentration, comparison with pure
cisplatin is of limited use. We could show that the PtII
complexes cleaved from B12 exerted a cytotoxicity compa-
rable to that of cisplatin itself. Cytotoxicity studies in vitamin
B12 free media showed a dependence on the addition of
transcobalamin II for B12–Pt(II) conjugates.
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Introduction
The treatment of diseases in current medicine widely
relies on the administration of target-specific but cell-
receptor-unspecific pharmaceuticals. Cell-specific targeted
drug delivery has, however, become a major issue in modern
molecular approaches to drug design and discovery [1].
Ideally, a pharmaceutical exclusively accumulates at the
target site and is readily eliminated from the rest of the body.
Much current research is, thus, currently performed in the
field of targeted drug delivery, based on nanoparticles,
organic copolymers, but also with small receptor binding
molecules [2–6]. The targeted drug delivery concept relies
on natural or artificial molecules which carry their bioactive
load to a specific site. At this site, the pharmaceutical is
released and exerts its activity. The feature of targeting is
particularly crucial in molecular imaging since the quality of
the images depends strongly on the target to nontarget ratio;
thus, the more specific the targeting, the better the inter-
pretation of the images [7, 8]. There are numerous modalities
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for targeting, encompassing in, e.g., nanomedicine, artificial
macromolecules such as dendrimers, carbon nanotubes, or
polyoxometallates derivatized with cell-specific receptor
binding functions such as antibodies, peptides, or small
molecules (and the bioactive substance). Metabolic tracers
are another class of targeting molecules in molecular
imaging but not in therapy; they accumulate owing to rapid
proliferation of cells. A prototype for such compounds is
18F-deoxyglucose [9], which is trapped in cells by irrevers-
ible inhibition of hexokinase. With the same concept, bio-
active drugs guided by targeting (small) molecules could be
delivered to specific sites provided that these bioconjugates
still follow the same metabolic pathway. Furthermore,
intracellular biochemical processes have to be involved in
the release of the drug after delivery to the cell but not
elsewhere. Whereas targeted cancer therapy with antibodies
is well developed, small carrier molecules are still rare. One
of the major problems related to small-molecule conjugation
of bioactive substances is the affection of the biological
properties of the carrier after conjugation to the imaging
agent or pharmaceutical.
Cobalamin (Cbl, vitamin B12) is essential for mammals.
Different cancer cell lines express a strongly increased
demand for Cbl. Cbl has been radiolabeled at various sites
on the corrin framework, generally on the b, d, or e pro-
pionamide chain of Cbl after hydrolysis to the corre-
sponding acids (Scheme 1) [10–17]. Those radiolabeled
Cbl showed high tumor accumulation, confirming their
adequacy as metabolic tracers and suitability for imaging
[18]. We showed recently that 99mTc-labeled Cbl deriva-
tives not binding to the transport protein transcobalamin II
(TCII) showed high site-specific accumulation and very
low kidney retention [19].
Whereas derivatizations with metal binding functional-
ities or bioactive molecules were generally performed at the
propionamide groups of the coring ring, at the 20-OH group
in the ribose [20–22], or by alkylation of CoI [23–26], we
have demonstrated that metal complexes can be bound
directly to the cyanide group in Cbl, thereby yielding a
heterodinuclear complex {B12–CN–M} in which Cbl acts as
a ligand [27]. In particular, cyanide in Cbl coordinated to
various square-planar PtII complexes such as cisplatin [28].
With PtII complexes in particular, the central {B12–CN–Pt
II}
motif was formed. An enzymatic assay showed that these
B12–Pt conjugates were still recognized by intracellular
adenosylation enzymes and were converted to adenosylco-
balamin (AdoCbl) [29]. During adenosylation, the PtII
complex was released by reduction of CoIII to CoII in Cbl.
Hence, conjugates of the general structure {B12–CN–Pt
II}
can be considered as prodrugs, suitable for Cbl-targeted PtII-
complex delivery to rapidly proliferating cells in which the
cytotoxic agent is released. In this paper, we present the
findings of in vitro cytotoxicity studies of the {B12–CN–Pt
II}
conjugates cis-[PtCl(NH3)2B12] (1), trans-[PtCl(NH3)2B12]
(3), and cis-[PtCl2(NH3)B12] (2) (Scheme 2) as a proof of
concept for vitamin B12 based metal-drug delivery.
Numerous PtII complexes have been screened for cyto-
toxicity during the search for cisplatin analogues with
cytotoxic activity [30]. However, the PtII complexes as
released from 1–3 (Scheme 2) are cisplatin-like but not
cisplatin. Besides NH3 and Cl, they contain one coordi-
nated cyanide. To our knowledge, the cytotoxicity of these
basic PtII complexes is not known since they are synthet-
ically difficult to access and have not been described in
literature. Accordingly, we present the bioactivity of these
complexes to assess their cytotoxicity after release from the
carrier B12 together with studies of the reactivity of the
released complexes toward nucleotides as models for
the DNA binding sites of cisplatin (analogues).
Materials and methods
General
All chemicals were purchased from Sigma, Fluka, and
Strem. Chemicals were of reagent grade and used without
further purification. The vitamin B12 complexes 1–3 were
Scheme 1 Basic structure of vitamin B12 derivatized at the b-
position with metal complexes [10–17]
Scheme 2 Structures of vitamin B12–Pt
II–complex conjugates {B12–
CN–PtII} 1–3 used in this study
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synthesized according to published procedures [29].
Ultraperformance liquid chromatography (UPLC) analyses
were performed using a Waters AcquityTM connected to an
HCT ion trap mass spectrometer (Bruker Daltonics). The
following liquid chromatography (LC) column, solvent
systems, and gradient were used: column, Macherey–Nagel
C-18ec Nucleosil RP (5-lm particle size, 100-A˚ pore size,
250 mm 9 3 mm); solvent system 1, 0.1% trifluoroacetic
acid (solvent A), methanol (solvent B); solvent system 2,
0.1% formic acid (solvent A), methanol (solvent B); sol-
vent system 3, 10 mM Et3Nac, pH 4.6 (solvent A),
methanol (solvent B); gradient 1, 0–5 min (75% solvent
A), 5–30 min (75% solvent A ? 0% solventA); gradient
2, 0–5 min (100% solvent A), 5–30 min (100% solvent
A ? 0% solvent A).
Chemical reduction of complexes 1–3
Reduction of cob(III)alamin to cob(II)alamin of derivatives
1–3 was performed in methanol, under a N2 atmosphere,
using 2 equiv of cobaltocene. Formation of cob(II)alamin
was monitored by UV–vis spectroscopy. The formation of
platinum complexes in the reaction mixture after release
from derivatives 1–3 was monitored by electrospray ioni-
zation (ESI) mass spectrometry (MS) and high perfor-
mance LC (HPLC) measurements (solvent system 1,
gradient 1, flow rate 0.5 mL min-1) and the formation of
HOCbl.
Chemical characterization of released Pt complexes 4–6
Isolation and characterization of cis-[Pt(CN)Cl(NH3)2] (4),
cis-[Pt(CN)Cl2(NH3)]
- (5), and trans-[Pt(CN)Cl(NH3)2]
(6) was not directly possible. Alternative tests were per-
formed to elucidate their chemical structures:
• Kurnakov test. Thirty minutes after chemical reduction
of 1–3 as described earlier, the solvent was evaporated
under vacuum. Ten equivalents of thiourea dissolved in
water was added to the mixture. After 5 min, the
solution was filtered and analyzed by UPLC–MS
(solvent system 2, gradient 2, flow rate 0.3 mL min-1).
Platinum released from conjugates 1 and 2 gave
the same product with a retention time of 11.5 min
and [M]? of 499.0, indicating the formation of
[Pt(CN)(thiourea)3]
? (7). Platinum released from com-
plex 3 gave a product with a retention time 4.2 min and
[M]? of 331.0, indicating the formation of [Pt(CN)(NH3)2
(thiourea)]? (8).
• 20-Deoxyguanosine interaction. 1 (6.5 lmol) was
reduced with cobaltocene (2 equiv) in methanol. After
the mixture had been stirred for 30 min, the solvent was
evaporated and the crude mixture was dissolved in
1.5 mL phosphate-buffered saline (PBS.) The solution
was filtered and added to 8 equiv of 20-deoxyguanosine.
Formation of complexes cis-[Pt(CN)(NH3)2(2
0-deoxy-
guanosine)]? (9) and cis-[Pt(CN)(NH3)(2
0-deoxygua-
nosine)2]
2? (10) was followed by UPLC–MS (solvent
system 2, gradient 2, flow rate 0.3 mL min-1), with a
retention time of 12.5 min and [M]? of 772.2. As a
control experiment, 6.5 lmol cisplatin was dissolved in
1.5 mL PBS containing 8 equiv of 20-deoxyguanosine.
Formation of cis-[PtCl(NH3)2(2
0-deoxyguanosine)]?
and cis-[Pt(NH3)2(2
0-deoxyguanosine)2]
2? was fol-
lowed by UPLC–MS (solvent system 2, gradient 2,
flow 0.3 mL min-1), with a retention time of 13.5 min
and [M]? of 762.2.
Kinetic interaction of GMP with cisplatin, 4, and 5
Complexes 1 and 2 (both 6.5 lmol) were reduced with
2 equiv of cobaltocene in methanol. After 30 min, the
solvent was evaporated and the crude mixture was dis-
solved in 1.5 mL PBS. The solution was filtered and added
to 50 equiv of GMP. The reaction was followed by UPLC–
MS every 4 h (solvent system 3, gradient 2, flow rate
0.3 mL min-1). As a control experiment, the reaction of
6.5 lmol cisplatin with 50 equiv of GMP in 1.5 mL PBS
was followed by UPLC–MS every 4 h under the same
conditions.
Cell lines
The human breast carcinoma MCF7 cell line was maintained
in minimum Eagle’s essential medium (MEM; Gibco) sup-
plemented with 10% fetal bovine serum (FBS; Gibco),
penicillin (100 U mL-1), and streptomycin (100 lg mL-1).
The human ovarian cancer A2780 cell line was maintained in
RPMI (Gibco) supplemented with 10% FBS (Gibco), peni-
cillin (100 U mL-1), and streptomycin (100 lg mL-1).
Cbl 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay
One thousand cells per well were seeded in 96-well pla-
tes 1 day before treatment. Cells were treated with cis-
platin, B12, cobaltocenium, 1, 2, 3, 4, 5, or 6 for 5 days, the
drug was removed, and cells were kept in fresh medium.
Upon addition of 20 lL per well of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution
(5 mg mL-1), the plates were incubated for 4–5 h at
37 C. One hundred microliters per well of lysis buffer
(20% sodium dodecyl sulfate, 50% dimethylformamide,
50% double-distilled H2O, pH \ 4.7) was added and the
plates were incubated overnight at 37 C. The solubilized
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formazan was quantified at 570 nm using a SpectraMax
M5 microplate reader. Optical density values were plotted
against the logarithm of drug (or derivative) concentration
and IC50 values were calculated from the regression curve.
Cbl/TCII MTT assay
To ensure a Cbl-dependent cytotoxic effect, RPMI deficient
in Cbl and folic acid (medium A) or MEM (Gibco) (medium
B), which does not contain Cbl in the original formulation,
was used. FBS was pretreated with fumed silica to reduce
interference of endogenous TCII/Cbl in the assay [31]. One
thousand cells per well were seeded in 96-well plates 1 day
before treatment using standard medium. After removal of
the growth medium, the cells were treated with cisplatin or
with 1, 2, or 3, or with 1, 2, or 3 in the presence of 1 equiv of
TCII for 1 day in medium A or medium B containing 10%
treated FBS. The drug was removed and the cells were kept
in fresh medium for an additional 4 days. Upon addition of
20 lL per well of MTT solution (5 mg mL-1), the plates
were incubated for 4–5 h at 37 C. One hundred microliters
per well of lysis buffer (20% sodium dodecyl sulfate, 50%
dimethylformamide, 50% double-distilled H2O, pH \ 4.7)
was added and the plates were incubated overnight at 37 C.
The solubilized formazan was quantified at 570 nm using a
SpectraMax M5 microplate reader.
Immunofluorescence
Indirect immunofluorescence experiments were performed
with MCF7 cells grown on glass coverslips. Upon fixation
in methanol (15 min, -20C), the cells were washed with
PBS. Blocking was carried out in PBS supplemented with
3% nonfat dry milk (blocking solution). The coverslips
were incubated overnight at 4 C in a humidified chamber
with c-H2AX (pSer139) antibody (mouse monoclonal,
Upstate Biotechnology) diluted 1:200 in blocking solution.
After they had been washed with blocking solution, the cells
were incubated with a Texas Red conjugated anti-mouse
antibody at 1:200 dilution in blocking solution for 1 h at
37 C. The nuclei were counterstained with 40,6-diamidino-
2-phenylindole (0.1 lg mL-1, Sigma). Images were acquired
using an Olympus IX81 fluorescence microscope.
Results and discussion
Reduction of Co(III) to Co(II) and isolation
of the released Pt(II) complexes
The enzymatic conversion of {B12–CN–Pt
II} derivatives to
AdoCbl by CobA enzyme has been reported previously
[29]. The corrinoid adenosylation pathway proposed
required the electron-transfer protein flavodoxin FldA and
the ferrodoxin Fpr as reductases for the CoIII ? CoII step.
Only in the presence of the corresponding enzyme and
ATP did further reduction of CoII to CoI take place with
concomitant formation of AdoCbl [32, 33]. For the purpose
of targeted metal complex delivery in our study, the first
reduction step is decisive. The PtII complexes from Cbl
derivatives 1–3 (Scheme 2) are released into the intracel-
lular space after the Cbl has entered the cells by receptor-
mediated endocytosis via the TCII receptor, but not before.
The release of the platinum complexes from 1–3 occurs
after enzymatic reduction of CoIII to CoII. The remaining
cob(II)alamin is then reduced to CoI and adenosylated to
coenzyme AdoCbl by adenosyltransferase [29]. After
reduction to CoII, the composition of the released PtII
complexes is an important question and, in particular, if the
cyanide ligand is still present on the released PtII complex
or is lost during reduction. It should be emphasized that the
cyanide is N-bound to PtII in {B12–CN–Pt
II} and it would
be uncommon to find an {Pt–NC} motif in the released
complex. Compounds 1–3 were electrochemically reduced
to release the b-axial complexes 4–6. After reduction,
HPLC evidenced the presence of exclusively aquo-Cbl,
assessing the cleavage of the complexes together with the
cyanide ligand. Although this is a very smooth and
straightforward method, the presence of large amounts of
supporting electrolyte as compared with the tiny amounts
of PtII complex made their characterization or isolation
impossible. Chemical reduction was more appropriate
since inert salts are absent and the process is faster. An
appropriate reducing agent is cobaltocene. Cobaltocene is a
noncoordinating molecule with a redox potential of about
-750 mV (vs. Ag?/AgCl) in methanol. This agent is ideal
for reduction of cob(III)alamin to cob(II)alamin and does
not further reduce CoII or the released platinum complexes.
Quantitative chemical reduction of 1–3 was smoothly
achieved with 2 equiv of cobaltocene in methanol and
under N2. The reaction was complete after 30 min at room
temperature. A typical UV–vis spectrum of the cob(II)
alamin produced together with an HPLC trace for HOCbl
formation is shown in Fig. 1.
The isolation of complexes 4 from 1, 5 from 2, and 6
from 3 (Scheme 3), released after cobaltocene reduction,
was not directly possible owing to the respective low
concentrations and insolubilities. Owing to their electro-
neutrality, compounds 4 and 6 as well as pure cisplatin
were not observed in ESI-MS. However, it has been shown
in the literature that characterization of PtII complexes
containing a 15N-enriched 15NH3 ligand is possible by 2D
[1H,15N] heteronuclear single quantum coherence (HSQC)
NMR spectroscopy [34]. The chemical shift dN is indica-
tive for the type of ligand trans to 15NH3 and it has been
shown that stronger trans ligands shift the 15N signal
36 J Biol Inorg Chem (2011) 16:33–44
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toward lower field. Thus, 15NH3 trans to H2O can clearly
be differentiated from 15NH3 trans to Cl
- [35–37]. Taking
the 15NH3 signal from cisplatin as a reference at
dN = -68.0 ppm, [
1H,15N] HSQC NMR spectroscopy of
the B12 conjugate 1 showed two nearby
15N signals, one at
-68.5 ppm, corresponding to 15NH3 trans to Cl
-, and one
at -72.9 ppm, assigned to the 15NH3 group trans to the Pt–
NC–Co moiety. When 4 was chemically cleaved from 1,
the NMR spectrum again showed two, now well-separated
signals. The 15NH3 signal trans to Cl
- remained
almost constant (-73.9 pm), whereas the second signal
(-40.7 ppm) shifted significantly to lower field. Since
cyanide is a very strong trans ligand, the latter signal
indicated the presence of a cyanide trans to 15NH3, thereby
further rationalizing the authenticity of 4 (see the electronic
supplementary material).
Dimethyl sulfoxide (dmso) is known to substitute Cl- in
PtII complexes [38]. Addition of dmso to the reaction
solution of 3 after cobaltocene reduction allowed for the
clear mass-spectrometric detection of trans-[Pt(CN)(dmso)
(NH3)2]
?. Although the signals were weak, the mass spectra
indicated that cyanide is still coordinated to the released PtII
complexes after reduction of 1–3 (see the electronic sup-
plementary material). An alternative method for the char-
acterization of the released platinum complexes relied on
the Kurnakov test, a method which allows one to distinguish
cis and trans isomers of dihalide–diamine PtII complexes
[39]. The test is based on the relative trans effect of
thiourea [ Cl- [ NH3 and involves, after reaction with
thiourea, the formation of [Pt(thiourea)4]
2? from
cis-[PtCl2(NH3)2] and trans-[Pt(NH3)2(thiourea)2]
2? from
trans-[PtCl2(NH3)2]. Since cyanide is known to be strongly
coordinated in platinum complexes, any substitution reac-
tions with thiourea in derivatives 4–6 should not affect the
cyanide ligand. Furthermore, according to the trans-effect
series CN- [ thiourea [ Cl- [ NH3, any ligand trans to
the cyanide should be replaced by thiourea following the
principles of the Kurnakov test.
Fig. 1 UV–vis spectra
associated with the reduction
of 3 from cob(III)alamin (a)
to cob(II)alamin (b) by
cobaltocene. High performance
liquid chromatography traces
monitored at 360 nm
of a solution of 3 (b),
hydroxocobalamin (HOCbl) (c),
and the cobalamin product
obtained after reduction of 3
with cobaltocene and
reoxidation in air (d)
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After reduction of 1–3 with cobaltocene, mixtures of
HOCbl and the respective PtII complexes 4–6 were formed.
The solvent was evaporated and the red residues were
dissolved in water containing a tenfold excess of thiourea.
After 30 min, the sample was filtered and analyzed by
LC–MS. In all three cases, HOCbl was observed. The
substitution reactions were fast and product formation was
complete after 1 h at a platinum-to-thiourea ratio of 1:10.
Since cyanide has a very strong trans effect, the reaction of
4 and 5 with thiourea should give the triply substituted
complex [Pt(CN){SC(NH2)2}3]
? (7) and the reaction of
thiourea with 6, a transplatin-type complex, should give
the monosubstituted complex trans-[Pt(CN)(NH3)2
{SC(NH2)}]
? (8) (Scheme 3). This predicted behavior was
confirmed and complexes 7 and 8 could clearly be identi-
fied as the major products by HPLC and ESI-MS (see the
electronic supplementary material).
Furthermore, complex 7 could be isolated by preparative
HPLC as a yellow powder. The 195Pt NMR spectrum of 7
gave a sharp signal at -4,130 ppm, a region in which
resonances of PtII complexes bound to three sulfur atoms
and one carbon atom are usually observed [40, 41]. The
infrared spectrum of 7 displayed a weak but characteristic
mCN band at 2,187 cm
-1, indicating that the platinum
complex was bound to the cyanide ligand via the carbon
atom [42]. Inspecting the basic structures of 1–3, we expect
that the platinum complex released after reduction will
bind the cyanide group via the nitrogen atom. Since all our
released complexes 4–6 showed the cyanide to be C-bound,
we conclude that isomerization of the cyanide from N- to
C-coordination took place very rapidly.
The platinum complexes 4–6 as released after chemical
or enzymatic reduction of cob(III)alamin in the intracel-
lular space are not cisplatin but cisplatin analogues. The
reactivity of these complexes toward their targets, guanine
or other nucleobases in DNA, is unknown. To assess the
affinity for nucleobases, we studied the interaction of 4–6
with 20-deoxyguanosine (Scheme 4).
According to the trans-effect series, in complex 4 one
chloride and eventually one NH3 should be replaced by a
base. To mimic physiological conditions, the reaction of,
e.g., 4 with 20-deoxyguanosine was performed in 10 mM
phosphate buffer (pH 7.4) with 0.9% NaCl as an electro-
lyte; eightfold excess of 20-deoxyguanosine was applied.
After chemical reduction of 1, the formation of products
was monitored by LC–MS as a function of time. Single
substitution should result in complex 9, and double sub-
stitution in complex 10 (Scheme 4). Figure 2 shows
Scheme 3 Reaction of
complexes 4–6 with thiourea.
Cp2Co cobaltocene
38 J Biol Inorg Chem (2011) 16:33–44
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representative UPLC chromatograms obtained from the
extrapolation of mass spectra of the substitution reactions
at the time points indicated. After 6 h at room temperature,
it is immediately obvious that both complex 9 and complex
10 were formed. Over time, the amount of 9 slowly
decreased, whereas the amount of the final product 10
increased. Thus, double substitution on PtII took place,
confirming the cisplatin-like behavior of the complexes
cleaved from their Cbl carriers.
To compare the reactivity of 4 and 5 with that of cis-
platin, we pursued the same strategy with the dianion
50-GMP (Scheme 5). The Cbl conjugates 1 and 2 were
reduced with cobaltocene, dried, and redissolved in 10 mM
phosphate buffer and 0.9% NaCl. For a qualitative com-
parison of the reaction rates, a 50-fold excess of GMP was
applied to ensure conditions for pseudo-first-order kinetics.
Product formation was monitored by LC–MS as a function
of time. The mobile phase used for these experiments
was crucial. With 0.1% formic acid in methanol as the
mobile phase, protonation of coordinated 50-GMP resulted
in loss of signals of the monosubstituted complexes
[PtCl(50-GMP)(NH3)2]
-, 11, and 12. In 10 mM [HNEt3]
?
[CH3CO2]
- (pH 7) and methanol, the signals for
[Pt(50-GMP)2(NH3)2]
2- and 13, respectively, could not be
observed anymore (Scheme 4). All platinum intermediates
and products could, however, be observed in UPLC–MS
when using [HNEt3]
?[CH3CO2]
- (pH 4.6) and methanol as
a mobile phase.
Qualitative kinetic measurements were performed for 4
and 5 after release from 1 and 2 and were compared with
those for cisplatin. Formation of 50-GMP-substituted
derivatives was plotted versus time by extrapolation of the
area obtained by UPLC–MS measurements for the indi-
vidual species.
Other studies typically used the monoaqua and diaqua
analogues of cisplatin for kinetic analysis of the reaction of
nucleotides and PtII complexes [43–45]. In our study, we
did not examine the aquation process since it was not
observed by ESI-MS. Bancroft et al. [44] observed no
evidence of either cis-[Pt(NH3)2(H2O)Cl]
? or cis-
[Pt(NH3)2(H2O)2]
2? during the reaction of cisplatin with
DNA, indicating that the hydrolyzed species reacted with
DNA as rapidly as they were formed. Furthermore, they
found that the rate constant of hydrolysis was equal to the
rate of DNA–Pt formation.
Under our conditions, cisplatin interacted with 50-GMP
to yield cis-[PtCl(GMP)(NH3)2]
- and cis-[Pt(GMP)2
(NH3)2]
2-, respectively. After about 5 h, the monosubsti-
tuted complex reached its maximum concentration (Fig. 3).
The amount of disubstituted complex steadily grew, with
complete formation after about 20 h. The behavior of 4 and
5 was qualitatively comparable. Both complexes were
substituted by one 50-GMP very rapidly. After less than 1 h,
the maximum concentration of monosubstituted compounds
11 and 12 was achieved (see the electronic supplementary
material). The kinetics of the second substitution were
similar for 11, 12, and cis-[PtCl(GMP)(NH3)2]
-. Formation
of the corresponding doubly substituted complex 13 was
complete after about 20 h. These kinetics measurements
followed qualitatively a consecutive A ? B ? C reaction
sequence. The very rapid formation of the monosubstituted
adducts 11 and 12 is a very important feature since it
enables retention of the cleaved platinum complexes in the
cells. Since the kinetics is comparable to that for cisplatin,
one could, at least from a chemical point of view, expect
similar biological behavior for 4–6.
Cytotoxicity studies
Having established the binding of the new platinum com-
plexes 4–6 with guanine derivatives, we considered it
important to investigate the cytotoxicity of these com-
plexes. Complexes 4–6 are the active drugs carried into the
cells by Cbl and released after reduction. Reactivity toward
50-GMP is an indication of but not a guarantee for cyto-
toxicity since other coordination sites may compete for PtII
binding in vivo. We therefore investigated the in vitro
cytotoxicity of compounds 4 and 5 with the cancer cell
lines A2780 and MCF7. IC50 values are given in Table 1.
Owing to the essentially nontoxic behavior of 3, the
cleavage product 6 was not further investigated. Compound
6 can form only DNA monoadducts, and complexes
Scheme 4 Interaction
of complex 4 with 20-
deoxyguanosine
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exerting a cisplatin-like behavior with DNA such as 4 and
5 are immediately more promising. However, it is known
that some exceptional, mono-DNA-adduct-forming PtII
complexes are highly cytotoxic [46].
Although the IC50 values of complexes 4 and 5 are
higher than those of cisplatin, they are comparable to those
of other cytotoxic or static agents [47]. One should keep in
mind that the IC50 values are not the only quality criteria
for successful therapeutic agents and are even sometimes
misleading. To evaluate the targeted drug delivery of the
{B12–CN–Pt
II} conjugates, we studied the in vitro cyto-
toxic behavior of 1–3 in the human breast carcinoma cell
line MCF7 and in the human ovarian cancer cell line
A2780. We showed in previous studies that the PtII com-
plexes remain stably bound to Cbl in human serum; hence,
any cytotoxicity found must be related to intracellular
release of the complexes rather than to decomposition in
the media [29]. It should be emphasized that Cbl is bound
in vivo to the transport protein TCII [48]. Cellular uptake
and internalization of Cbl occurs upon binding of holo-TCII
to the membrane TCII receptor (rTCII). After degradation,
Cbls are released and enter the enzymatic cycles. Reports
in the literature describe the uptake of Cbl derivatives that
are TCII nonbinders along so far not fully elucidated
pathways [19]. The targeted approach is, however, based
on holo-TCII, able to bind rTCII. We initially compared
1–3 with cisplatin despite the fact that the former com-
plexes are prodrug-like compounds, probably unable to
freely diffuse into the cell, in contrast to cisplatin. There-
fore, in the case of 1–3, the concentration of active plati-
num complexes in the intracellular space is governed by
the rate of internalization and might be significantly lower
than what is achieved with cisplatin. As outlined later, the
amount of Cbl–Pt conjugates bound to TCII available in
the medium is decisive for cytotoxicity, since conjugates
not bound to TCII are unlikely to enter the cells.
Cells were plated in 96-well plates at 5,000 cells per
well in 100 lL RPMI 1640 or MEM containing 10% of
FBS. After 24 h, the cells were treated with cisplatin, 1, 2,
and 3 at different concentrations. To assess the potency of
Fig. 2 Ultraperformance liquid chromatography chromatogram and corresponding mass spectrometry spectra of the substitution reaction of 4
with 20-deoxyguanosine
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Scheme 5 Interaction of
cisplatin, 4, and 5 with GMP
Fig. 3 Time-dependent
formation of mono-GMP-
and bis-GMP-substituted
complexes, starting from
cisplatin, 4, and 5
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1–3, cell viability after 5 days of treatment with the com-
pounds was evaluated by MTT assays.
We found that the Cbl conjugates 1–3 were less active
than cisplatin against MCF7 and A2780 cells. Figure 4
shows a concentration–activity comparison. The IC50 val-
ues are given in Table 1. Conjugate 1 is the most active
{B12–CN–Pt
II} compound, whereas 2 and 3 are essentially
inactive. Since the PtII complex 6 as cleaved from 3 can
form only monoadducts with DNA, its nonactivity is rea-
sonable. However, since 4 and 5 as released from 1 and 2,
respectively, show the same behavior toward thiourea and
50-GMP (vide infra), the nonactivity of 2 is not immedi-
ately obvious. We speculate that there is a diffusion-con-
trolled uptake mechanism (e.g., via cation channels), which
would favor the uptake of cationic 1 over neutral 2,
resulting in an enhanced cytotoxic effect as observed for 1.
For the time being, questions about quantification and the
pathway of uptake remain to be elucidated.
Role of TCII
As mentioned before, the plasma transport of Cbl or Cbl
derivatives to all tissues or cells is mediated by TCII. Holo-
TCII is taken up by receptor-mediated endocytosis via
rTCII [49]. Expression of rTCII is important for the cellular
uptake of Cbl, although information on the level of rTCII
expression in A2780 and MCF7 cell lines is not available
to our knowledge. In addition, the concentration of TCII in
the cell culture medium determines the level of Cbl–TCII
complexes that will undergo internalization [31]. The
results of the cytotoxicity assays described earlier might
have been influenced by these factors and passive inter-
nalization of 1–3 also have to be taken into account. To
assess this issue, we set out to determine the effect of TCII
on cytotoxicity upon addition of apo-TCII to the media,
using very low concentrations of 1–3. To measure
TCII/Cbl-dependent cytotoxicity, RPMI 1640 deficient in
Cbl and folic acid (medium A) was used for A2780 and
commercial MEM (medium B) was used for for MCF7,
since the formulation of MEM is deficient in Cbl. The
medium was supplemented with 10% FBS pretreated with
fumed silica to reduce interference of bovine TCII–Cbl in
the bioassay.
Cells were plated in 96-well plates at 1,000 cells per well
in 100 lL of medium A or medium B containing 10%
pretreated FBS. After 24 h, the cells were treated with
cisplatin, compounds 1, 2, apo-TCII ? 1, or apo-TCII ? 2
at 3.125, 1.56, and 0.78 lM. After 24 h the compounds
were removed and the cells were kept in standard medium
for 4 days. Cell viability was assessed by MTT assays.
Figure 5 shows that compounds 1 and 2 were not active at
all in the absence of apo-TCII; thus, passive diffusion
played a minor role in the observed cytotoxicity. In contrast,
in the presence of apo-TCII, analogues 1 and 2 exhibited
detectable toxicities even at these low concentrations,
indicating that TCII-mediated internalization had occurred.
Interaction with DNA: immunofluorescence studies
Whereas cytotoxicity can be induced by many biological
events, it has been thoroughly established for PtII com-
plexes that DNA strand cross-links are the major mode of
Table 1 Comparison of the IC50 values of cisplatin and the {B12–
CN–PtII} conjugates 1–3 and the cleaved complexes 4 and 5
IC50 (lM)
A2780 MCF7
Cisplatin 0.3 1.2
1 8 13
2 48 [100
3 54 88
4 6 5.5
5 4 7
Fig. 4 Cytotoxicity of cisplatin, 1, 2, and 3 for MCF7 and A2780
after 5 days of treatment
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action [38, 44, 50, 51]. The ability of compounds 1, 2, and
5 to interact with DNA and induce DNA damage was
investigated by the formation of c-H2AX foci in MCF7
cells. Cells were grown on glass coverslips and treated with
50 lM compound 1, a concentration that corresponds to its
IC90 in the MTT assay and that exerted an effect compa-
rable to that of cisplatin at its IC90. As positive control,
cells were irradiated with 10 Gy or treated with 3 lM
cisplatin (IC90). The cells were examined at the time points
indicated (24, 72, and 144 h). Since the maximum con-
centration used in the MTT assay was 100 lM, corre-
sponding to IC35 for compound 2, immunofluorescence
studies of compound 1, 2, 5, and cisplatin were carried out
using their corresponding IC35 values (see the electronic
supplementary material). As shown in Fig. 6, 24 h of
treatment with compound 1 induced c-H2AX foci dis-
playing an intensity similar to that of cisplatin-treated cells.
However, the signal decreased more rapidly in cells treated
with compound 1 than in cisplatin-treated cells, likely
indicating a more efficient repair in the former case.
Conclusions
We have studied the mode of action of the vitamin B12–Pt
II
conjugates 1–3 for targeted drug delivery. To mimic
biological reduction in cells, chemical reduction of 1–3
with cobaltocene yielded HOCbl and the corresponding PtII
complexes 4–6 released from B12, The reactivity of these
cisplatin analogues was studied with thiourea, 20-deoxy-
guanosine, and GMP. The reactivities of 4 and 5 with GMP
compared well with the reactivity of cisplatin. Accord-
ingly, isolated 4 and 5 after B12 release displayed cyto-
toxicity comparable to that of cisplatin. Preliminary
cytotoxicity studies of 1–3 showed a lower effect than for
cisplatin, probably owing to a low, receptor-mediated
uptake of the {B12–CN–Pt
II} conjugates. Addition of apo-
TCII to the cell media substantially increased the cytotoxic
effect, underlining the limiting aspect of uptake and cor-
relation to cytotoxicity. We conclude that {B12–CN–Pt
II}
conjugates can be considered as prodrugs since they release
their cytotoxic cargo, the PtII complexes in this case, only
in the intracellular space. Currently, we are investigating
the amount of uptake of {B12–CN–Pt
II} and therapeutic
action.
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